glp-1 latest news Pipeline Update: May 2026 - Prime Therapeutics GLP-1 Overdoses Are Rising as

Additional studies have confirmed the efficacy of the DASH/SDR diet in managing hypertension, lowering 24-hour ambulatory systolic and diastolic blood pressure, and improving LV diastolic function, arterial elasticity, and ventriculararterial coupling in HFpEF patients [61, 62]

In comparing GLP-1RAs with these medications, no significant difference in intestinal obstruction risk was observed

Wanting to have more energy to play outside with her son, she started walking more in her Iowa town, eventually challenging herself to run one mile daily on the treadmill in 2022

[1] World Obesity Atlas 2024 [2] World Obesity Atlas 2023 Related Links:

Therefore, it is recommendable to decrease the sulphonylurea or insulin dose in patients on sulphonylurea or insulin therapy who start a GLP-1 receptor agonist to reduce the risk of hypoglycemic episodes [137]

These effects far exceed those of most lifestyle intervention studies, leading to a rapid improvement in clinical outcomes with GLP-1RAs in obesity management